Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

87.41 +0.59 (+0.68%)
Official Closing Price Updated: 7:00 PM EDT, Aug 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,801,218
Open 86.53
Bid (Size) 87.26 (1)
Ask (Size) 92.36 (2)
Prev. Close 86.82
Today's Range 86.05 - 87.53
52wk Range 70.89 - 95.72
Shares Outstanding 2,531,374,696
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
CNBC's Final Trades: Iron Mountain, Porsche And This Health Care Company
On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Iron Mountain Inc (NYSE: IRM) represents “the best of both worlds.” &ldqu 
Via Benzinga

Performance

YTD
+13.71%
+13.71%
1 Month
-5.79%
-5.79%
3 Month
-0.26%
-0.26%
6 Month
+12.67%
+12.67%
1 Year
+16.05%
+16.05%

More News

Read More
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
JetBlue, Crowdstrike Get CNBC Fast Money Mentions, With This Stock Popping 0.94%
Via Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Via Benzinga
FDA Removes Clinical Hold On Celyad's Colorectal Cancer Trial
Via Benzinga
Seagen Q2 Earnings - Better Than Expected, Mum On M&A, Lifts Outlook
Via Benzinga
AstraZeneca and Merck Receives European Commission Approval For Expanded Use In Breast Cancer Therapy
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Where Merck & Co Stands With Analysts
Via Benzinga
Keytruda, Gardasil Boost Merck's Q2 Revenues, Tightens Annual Guidance
Via Benzinga
Merck & Co: Q2 Earnings Insights
Via Benzinga
3 Pharma Stocks' Post-Earnings Price Moves
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Meta and Qualcomm Miss— Will Tech Investors Shrug Off These Reports Too?
Via Benzinga
Merck Eyes 50-Day Line As Profit Triples And Keytruda Passes $5 Billion Mark
Via Investor's Business Daily
7 Stocks to Buy on the Dip
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.